All In Biotech

Drug Trial Radar · NCT05907954

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jul 3, 2023

Primary completion

Apr 30, 2027

Study completion Apr 30, 2030

Sponsor

Lead sponsor
IDEAYA BiosciencesIndustry
Sponsor type
Industry
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

Conditions

  • Uveal Melanoma

Interventions

  • DarovasertibDrug

    Oral, potent, selective inhibitor of Protein Kinase C

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) and significant laboratory abnormalitiesTime frame: from first dose to 28 days after last dose of therapy, approximately 18 months
  2. Cohort 1 (enucleation): Number of patients converted from requiring enucleation to radiationTime frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
  3. Cohort 2 (plaque brachytherapy): Estimated change in modeled radiation doseTime frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
  4. Cohort 3 (patients with small UM tumors): Number of patients with clinical benefit per protocol-defined UM response criteriaTime frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • Moores Cancer Center

    La Jolla, California

  • Stanford Cancer Institute

    Palo Alto, California

  • University of Miami

    Miami, Florida

  • The Cancer and Hematology Centers

    Grand Rapids, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Northwell

    Manhasset, New York

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • St. Vincent's Health Sydney

    Sydney, New South Wales, Australia

  • Alfred Health

    Melbourne, Victoria, Australia

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Institute Curie

    Paris, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Fondazione IRCCS Istituto Nazionale Tumori

    Milan, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.